期刊文献+

非线性混合效应模型法研究卡马西平在癫痫儿童中的群体药动学 被引量:8

下载PDF
导出
摘要 目的:考察卡马西平(CBZ)在癫痫儿童中的群体药动学参数。方法:采集我院的866例儿童癫痫患者服用CBZ常规治疗及监测的资料数据,利用Michaelis-Menten一级消除药物动力学模型,非线性混合效应模型程序估算癫痫儿童服用CBZ的群体药动学参数。结果:癫痫儿童卡马西平群体药动学主要参数Ke、Vd、CL在单用CBZ组分别为0.091h-1、0.502L.kg-1和0.046L.h-1.kg-1;性别、身高以及合并氯硝西泮、妥吡酯对CBZ清除率未见明显影响;儿童年龄、体质量、肝肾功能异常以及合并丙戊酸、苯巴比妥、苯妥因为CBZ清除率影响的重要因素,并且均增加CBZ的清除率。结论:根据癫痫儿童的群体药动学模型,结合患儿的年龄、体质量、肝肾功能、服药剂量以及合并用药等资料,估算其清除率,预测患儿体内的药物浓度,制定个体化给药方案。
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2007年第7期1001-1004,共4页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献18

  • 1中华人民共和国药典委员会编.临床用药须知[S].2000:78.
  • 2Sheiner LB. Rosenberg B. Marathe W. Estimation of population characteristics of pharmacokinetic parameters from routine elinical date[J]. Pharrnacokinet Biopharrn, 1997. 25(2):445.
  • 3Sheiner LB. The population approach to pharmacokinetinetic date analysis; rationale and standard date analysis methods[J]. Drug Metab Rev, 1994,25 : 153-155.
  • 4Beal SK. Population pharmacokinetic date and parameter estumation based on their first two statistical moments[J]. Drug Metab Rev, 1994,25 : 173-175.
  • 5Sheiner LB. An introduction to mixed effect model:concepts, definitions, and justification [J]. J pharmackinet Biopharm, 1991,19(3):113.
  • 6郑萍,胡敏燕,刘世霆,杨凌.卡马西平吸收的多峰现象[J].中国临床药学杂志,1999,8(3):184-185. 被引量:18
  • 7Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients[J]. Br J Clin Pharmacol, 2001,51 (6) :567,576.
  • 8Sheiner LB. An introduction to mixed effect model: concepts, definitions, and justification [J]. J pharmackinet Biopharm, 1991,19(3):113.
  • 9焦正,钟明康,施孝金,胡敏,李中东,王大猷,张莉莉,张静华,王宏图.NONMEM法考察中国癫痫患者丙戊酸和卡马西平的药动学相互作用[J].中国药学杂志,2004,39(2):130-132. 被引量:19
  • 10Yukawa E, Aoyama T, Detection of Carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic date[J]. J Clin pharmacol, 1996, 36: 752- 759.

二级参考文献20

  • 1钟明康,张静华,王宏图,印绮平,余自成.卡马西平的药物动力学特性[J].中国医院药学杂志,1995,15(1):24-25. 被引量:8
  • 2范洪斌.卡马西平药疹26例临床分析[J].皮肤病与性病,1996,18(4):14-14. 被引量:9
  • 3[1]Bertilsson L,Tomson T. Clinical Pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. A update. Clin Pharmacokinet, 1986;11(3):197~8
  • 4[2]Guidance for Industry population pharmacokinetics. Feb 1999, FDA, http://www.fda.gov/ohrms/dockets/98fr/970383gd.pdf. 2001-12-30 last visited
  • 5[4]Wade JR, Kelman AW, Howie CA et al. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. Journal of pharmacokinetics and biopharmaceutics, 1993;2(21):209~22
  • 6[6]Yukawa E, Aoyama T. Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data. J Clin Pharmacol, 1996;36(8):752~9
  • 7[7]Gray AL, Botha JH, Miller R. A model for the determination of carbamazepine clearance in children on mono- and polytherapy. Eur J Clin Pharmacol, 1998;54(4):359~62
  • 8[8]Graves NM, Brundage RC, Wen Y et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy, 1998;18(2):273~81
  • 9[9]Chan E, Lee HS, Hue SS. Population pharmacokinetics of carbamazepine in Singapore epileptic patients. Br J Clin Pharmacol, 2001;51(6):567~76
  • 10[10]Delgado-Iribarnegarary MF, Santos-Buelga D, Garcia-Sanchez MJ et al. Carbamazepine population pharmacokinetics in children: Mixed-effect models. Ther Drug Monit, 1997;19(2):132~9

共引文献42

同被引文献71

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部